genOway Accelerates International Business Expansion
genOway, a French company specializing in preclinical models, has established a 100% subsidiary, genOway Japan. Dr. Hideki Hanaoka has been appointed as CEO to strengthen the company's research and development support in the Japanese market.
📋 Article Processing Timeline
- 📰 Published: April 7, 2026 at 18:30
- 🔍 Collected: April 7, 2026 at 10:00
- 🤖 AI Analyzed: April 21, 2026 at 00:29 (326h 28m after Collected)
- Dr. Hideki Hanaoka appointed as Representative Director of genOway Japan
- Mr. Philippe Fauchet appointed as Chairman of the Board of genOway Japan
Lyon (France) – April 7, 2026 – genOway (Euronext Growth™ – ALGEN – ISIN: FR0004053510), a company specializing in the design of predictive preclinical solutions that more faithfully reproduce humans and their diseases so that pharmaceutical researchers can select the most effective and safe drug candidates, today announced the establishment of a new company, genOway Japan, a wholly owned subsidiary.
Japan is the world's third-largest preclinical research market after the US and China, and it is also a historic market for genOway. The company's clients include major players in the field such as Takeda Pharmaceutical, Eisai, and Ono Pharmaceutical. Notably, genOway's technology contributed to the development of Opdivo, a breakthrough immunotherapy drug originating from the research of Nobel laureate Dr. Tasuku Honjo. Innovation in the biotechnology sector is a major national priority for the Japanese government, with massive investments and active participation by Japanese biotech companies. With the establishment of genOway Japan, the company aims to further contribute to this field.
genOway's strategy through establishing its first subsidiary in Japan is to replicate the business model that has been successful in Europe and the US. By establishing a local base, it will promote close dialogue with customers and provide Japanese stakeholders, through a local business team, with the same scientific value-add that is already highly regarded in Western markets.
The company plans to build a fully autonomous business team consisting of five scientists within one year.
Dr. Hideki Hanaoka, who has more than 20 years of experience in Japan's life sciences industry, genomics, and cellular technology fields, has been appointed as Representative Director. Furthermore, the company decided to entrust the role of Chairman of the Board of Directors of the subsidiary to an independent director, requesting Mr. Philippe Fauchet to take on the position. Mr. Fauchet has a proven track record of decades at the core of Japan's biopharmaceutical innovation ecosystem and brings highly valued strategic expertise and precious localized insights to the subsidiary.
[Comment from Alexandre Fraichard, CEO of genOway] 'Expanding our international presence, primarily in Asia, is one of the factors driving genOway's growth under our strategic plan "Route50+DATA", which aims to achieve 50 million euros in revenue by 2028. We aim to establish leadership in the Japanese market for innovative preclinical models and, as part of the "Route50+DATA" plan, achieve revenues of 5 to 10 million euros in the Japanese market.'
Comment from Dr. Hideki Hanaoka, Representative Director of genOway Japan: 'As a global leader in high value-added genetically modified models, genOway provides advanced humanized models, particularly in the fields of immuno-oncology and immune-inflammation. By enabling researchers to predict the efficacy of novel treatments more accurately, we will accelerate the drug discovery process. This world-class'
- Mr. Philippe Fauchet appointed as Chairman of the Board of genOway Japan
Lyon (France) – April 7, 2026 – genOway (Euronext Growth™ – ALGEN – ISIN: FR0004053510), a company specializing in the design of predictive preclinical solutions that more faithfully reproduce humans and their diseases so that pharmaceutical researchers can select the most effective and safe drug candidates, today announced the establishment of a new company, genOway Japan, a wholly owned subsidiary.
Japan is the world's third-largest preclinical research market after the US and China, and it is also a historic market for genOway. The company's clients include major players in the field such as Takeda Pharmaceutical, Eisai, and Ono Pharmaceutical. Notably, genOway's technology contributed to the development of Opdivo, a breakthrough immunotherapy drug originating from the research of Nobel laureate Dr. Tasuku Honjo. Innovation in the biotechnology sector is a major national priority for the Japanese government, with massive investments and active participation by Japanese biotech companies. With the establishment of genOway Japan, the company aims to further contribute to this field.
genOway's strategy through establishing its first subsidiary in Japan is to replicate the business model that has been successful in Europe and the US. By establishing a local base, it will promote close dialogue with customers and provide Japanese stakeholders, through a local business team, with the same scientific value-add that is already highly regarded in Western markets.
The company plans to build a fully autonomous business team consisting of five scientists within one year.
Dr. Hideki Hanaoka, who has more than 20 years of experience in Japan's life sciences industry, genomics, and cellular technology fields, has been appointed as Representative Director. Furthermore, the company decided to entrust the role of Chairman of the Board of Directors of the subsidiary to an independent director, requesting Mr. Philippe Fauchet to take on the position. Mr. Fauchet has a proven track record of decades at the core of Japan's biopharmaceutical innovation ecosystem and brings highly valued strategic expertise and precious localized insights to the subsidiary.
[Comment from Alexandre Fraichard, CEO of genOway] 'Expanding our international presence, primarily in Asia, is one of the factors driving genOway's growth under our strategic plan "Route50+DATA", which aims to achieve 50 million euros in revenue by 2028. We aim to establish leadership in the Japanese market for innovative preclinical models and, as part of the "Route50+DATA" plan, achieve revenues of 5 to 10 million euros in the Japanese market.'
Comment from Dr. Hideki Hanaoka, Representative Director of genOway Japan: 'As a global leader in high value-added genetically modified models, genOway provides advanced humanized models, particularly in the fields of immuno-oncology and immune-inflammation. By enabling researchers to predict the efficacy of novel treatments more accurately, we will accelerate the drug discovery process. This world-class'